Research map: FLT3‐ITD Measurable Residual Disease in Acute Myeloid Leukemia: Recommended, but Not Yet Self‐Sufficient

Back to the article

Papers in this map

  1. Genomic Classification and Prognosis in Acute Myeloid Leukemia · Elli Papaemmanuil · 2016 · 4535 citations · Cited by this paper
  2. Low‐Dose Chidamide Maintenance Therapy After Hematopoietic Stem Cell Transplantation for T‐Cell Acute Lymphoblastic Leukemia: A Case Series · 2026 · Related
  3. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN · Hartmut Döhner · 2022 · 3298 citations · Cited by this paper
  4. Decoding the Heterogeneity of Diffuse Large B‐Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B‐Cell Lymphoma Cell Lines · 2026 · Related
  5. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3 · Mark J. Levis · 2024 · 222 citations · Cited by this paper
  6. Sequential BV‐AVD Therapy in Richter Transformation: Insights Into the Management of Elderly Patients · 2026 · Related
  7. Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin · Laura Katharina Schmalbrock · 2021 · 174 citations · Cited by this paper
  8. Nucleoporin 98 Rearrangements in Acute Leukemia: A Genomic Landscape Study · 2026 · Related
  9. Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia · Tim Grob · 2022 · 155 citations · Cited by this paper
  10. Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study · 2026 · Related
  11. A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations · Mark J. Levis · 2018 · 154 citations · Cited by this paper
  12. Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States · 2026 · Related
  13. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant · Laura Williams Dillon · 2023 · 152 citations · Cited by this paper
  14. Integrative Transcriptomic and Functional Analysis of PKMYT1 Reveals a Potential Therapeutic Target in Chronic Lymphocytic Leukemia · 2026 · Related
  15. Molecular profile of FLT3 -mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib · Catherine Choy Smith · 2022 · 98 citations · Cited by this paper
  16. Matching‐Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second‐Line Myelofibrosis Therapy · 2026 · Related
  17. Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML · Jad Othman · 2024 · 93 citations · Cited by this paper
  18. Clinical Significance of FLT3‐ITD Variation Allele Frequency in Acute Myeloid Leukemia: A Multicenter Study · 2026 · Related
  19. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome · Sun Loo · 2022 · 91 citations · Cited by this paper
  20. Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T‐Cell Infusion: A Case Report With Mechanistic Insight · 2026 · Related
  21. Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia · Laura Williams Dillon · 2024 · 63 citations · Cited by this paper
  22. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party · Jacqueline J Cloos · 2025 · 63 citations · Cited by this paper
  23. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation · Clara Philine Wienecke · 2024 · 43 citations · Cited by this paper
  24. Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin · Frank G. Rücker · 2024 · 21 citations · Cited by this paper
  25. Comprehensive review and evaluation of computational methods for identifying FLT3-internal tandem duplication in acute myeloid leukaemia · Dan‐Yang Yuan · 2021 · 16 citations · Cited by this paper
  26. FLT3 -ITD measurable residual disease from the QuANTUM-First trial · Mark J. Levis · 2025 · 9 citations · Cited by this paper
  27. ELN-DAVID recommendations for NGS-based FLT3 -ITD MRD testing for patients with acute myeloid leukemia · Christopher Simon Hourigan · 2026 · 4 citations · Cited by this paper
  28. Prognostic impact of FLT3 -ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy · Nicolas Duployez · 2026 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)